IP Library Granted Patent US 12,358,888
Granted Patent B2
US 12,358,888 · App. 18/593,597 · Granted Jul 15, 2025

Vaporizable alkaloid compositions and methods of use thereof

Inventors: Charlotte L. Owen (Seguin, TX); Richard Avila, Jr. (Prescott Valley, AZ); Geoff W. Habicht (Phoenix, AZ)
Assignee: Ready Mix Naturals, LLC
C07D401/04A24B15/167A24B15/301
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,358,888
App. No.
18/593,597
Granted
Jul 15, 2025
Kind
B2
Abstract

In various embodiments of the present disclosure, vaporizable alkaloid compositions are described that are capable of forming an inhalable vapor when dispensed from an electronic device such as an e-cigarette. The compositions herein comprise a substituted pyridine compound in combination with a chemosensory irritant, which in certain examples comprises a spice additive having a spiciness of from about 1,000 to about 20,000,000 Scoville Heat Units (SHU). A series of vaporizable alkaloid compositions having decreasing (w/v) amounts of substituted pyridine compound are provided as part of a smoking cessation program.

Claims (35)

1. A vaporizable alkaloid composition, comprising:

at least one substituted pyridine compound of Formula (I), or salt or mixed salt thereof;

wherein R 5 is CH 3 , and R 1 , R 2 , R 3 , and R 4 are independently selected from alkyl, H, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, and substituted alkenyl, with the proviso that at least one of R 1 , R 2 , R 3 , and R 4 is not H,

at least one flavoring agent selected from the group comprising geraniol, geranial, valeric acid, ethyl maltol, ethyl butyrate, ethyl acetate, maltol, ethyl 3-methyl-3-phenylglycidate, furaneol, methyl cyclopentenolone, methyl cyclopentenolone, ethyl cyclopentenolone, δ-decalactone, γ-decalactone, α-nonalactone, β-nonalactone, cis-3-hexanol, iso-amyl acetate, ethyl-2-methyl butyrate, butyric acid, ethyl butyrate, 2-methylbutyric acid, benzyl alcohol, ethyl hexanoate, benzaldehyde, iso-amyl isovalerate, hexanoic acid, ethyl propionate, γ-undecalactone, acetyl propionyl, raspberry ketone, furfural, 5-methylfurfural, maltol, 2-acetylpyrazine, 2,3,5-trimethylpyrazine, 2-acetylpyrrole, 2-isopropyl-4-methylthiazole, 2-isobutylthiazole, furfuryl mercaptan, thiomenthone, p-menthene-8-thiol, tropathiane, hexyl acetate and mixtures thereof wherein the vaporizable alkaloid composition is entirely devoid of (R) or (S) nicotine.

2. The vaporizable alkaloid composition of claim 1 , wherein the substituted pyridine compound, or salt thereof, or mixed salt thereof, is selected from (R) or (S)-2-methyl-3-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-4-methyl-3-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-3-methyl-5-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-2,6-dimethyl-3-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-2,4-dimethyl-5-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-2,3-dimethyl-5-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-2,4-dimethyl-3-(1-methylpyrrolidin-2-yl)pyridine, (R) or (S)-2,5-dimethyl-3-(1-methylpyrrolidin-2-yl)pyridine, and (R) or (S)-3,4-dimethyl-5-(1-methylpyrrolidin-2-yl)pyridine.

3. The vaporizable alkaloid composition of claim 1 , wherein the substituted pyridine compound, or salt thereof, or mixed salt thereof, is (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine.

4. The vaporizable alkaloid composition of claim 1 , wherein the at least one substituted pyridine compound of Formula (I), or salt thereof, or mixed salt thereof, consists of a mixture of (S)-2-methyl-3-(1-methylpyrrolidin-2-yl)pyridine free base and (2S)-1-methyl-2-(6-methylpyridin-3-yl)pyrrolidin-1-ium citrate/acetate mixed salts.

5. The vaporizable alkaloid composition of claim 1 , further comprising at least one chemosensory irritant.

6. The vaporizable alkaloid composition of claim 5 , wherein the at least one chemosensory irritant is selected from the group consisting of oleocanthal, 4-hydroxy-2-nonenal, 4-oxo-2-nonenal, allicin, allyl isothiocyanate, icilin, polygodial, cinnamaldehyde, trans-p-methoxycinnamaldehyde, methyl syringate, 2-chlorobenzylidene malononitrile, 1-chloroacetophenone, ethyl bromoacetate, 4-hydroxyhexenal, toluene diisocyanate, p-benzoquinone, methyl p-hydroxybenzoate, flufenamic acid, niflumic acid, mefenamic acid, diclofenac, hydroxy-α-sanshool, 6-paradol, linalool, carvacrol, eugenol, thymol, vanillin, methyl eugenol, 2,6-dimethylphenol, 2,5-dimethylphenol, 3,4-dimethylphenol, 2,6-diisopropylphenol, caffeine, farnesyl thiosalicylic acid, 4-allylanisole, curcumin, niacin, camphor, olvanil, arvanil, anandamide, cannabidiol, Δ 9 -tetrahydrocannabinol, baicalein, baicalin, wogonin, norwogonin, oroxylin A, β-sitosterol and mixtures thereof.

7. The vaporizable alkaloid composition of claim 5 , wherein the chemosensory irritant is a spice additive exhibiting a spiciness of from about 1,000 to about 20,000,000 Scoville Heat Units (SHU).

8. The vaporizable alkaloid composition of claim 7 , wherein the spice additive is selected from the group consisting of capsaicin, dihydrocapsaicin, norcapsaicin, nordihydrocapsaicin, homocapsaicin, homodihydrocapsaicin, gingerol, piperine, Shogaol, isopiperine, chavicine, isochavicine, 2-piperamine, piperanine (4,5-dihydropiperine), piperamide, 4-pipericide, piperyline, piperlonguminine, piperettine, piperdardine (6,7-dihydropiperettine), 5-sarmentodine, 6-sarmentine, 7-trichostachine, and mixtures thereof.

9. The vaporizable alkaloid composition of claim 8 , wherein the spice additive is capsaicin or a mixture of capsaicinoids.

10. The vaporizable alkaloid composition of claim 1 , further comprising at least one solvent.

11. The vaporizable alkaloid composition of claim 10 , wherein the at least one solvent is selected from the group consisting of propylene glycol, water, ethanol, glycerin, and mixtures thereof.

12. The vaporizable alkaloid composition of claim 1 , further comprising an organic acid selected from the group consisting of formic acid, acetic acid, trifluoroacetic acid, aspartic acid, butanoic acid, butyric acid, 2-methylbutyric acid, 3-methylbutyric acid, benzoic acid, caprylic acid, citric acid, crotonic acid, ethylenediaminetetraacetic acid, fumaric acid, gluconic acid, glutamic acid, glyceric acid, glycolic acid, lactic acid, lauric acid, levulinic acid, maleic acid, malic acid, malonic acid, mandelic acid, methane sulfonic acid, oxalic acid, phenylacetic acid, phthalic acid, picric acid, propionic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, tartronic acid, valeric acid, and mixtures thereof.

13. The vaporizable alkaloid composition of claim 12 , wherein the organic acid is selected from the group consisting of citric acid, acetic acid, benzoic acid, tartaric acid, lactic acid, salicylic acid, malic acid, levulinic acid, and mixtures thereof.

14. The vaporizable alkaloid composition of claim 12 , wherein the molar ratio of total substituted pyridine compound to total organic acid is about 25:1 to about 75:1.

15. The vaporizable alkaloid composition of claim 1 , further comprising at least one chemosensory irritant and at least one solvent.

16. The vaporizable alkaloid composition of claim 1 , further comprising at least one chemosensory irritant and at least one flavoring agent.

17. The vaporizable alkaloid composition of claim 1 , further comprising at least one solvent and at least one flavoring agent.

18. A vaporizable alkaloid composition comprising:

from about 1 wt. % to about 80 wt. % of (S)-2-methyl-5-(1-methylpyrrolidin-2-yl) pyridine;

from about 0.05 wt. % to about 1.5 wt. % in total of at least one organic acid;

and

remainder solvent,

wherein the weight percentages are based on the total weight of the vaporizable alkaloid composition; and

wherein the molar ratio of moles of (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine to total moles of organic acid is from about 25:1 to about 75:1.

19. The vaporizable alkaloid composition of claim 18 , further comprising from about 0.0001 wt. % to about 0.50 wt. % of a spice additive having a spiciness of from about 1,000 to about 20,000,000 Scoville Heat Units (SHU).

20. The vaporizable composition of claim 18 , wherein the molar ratio of moles of (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine to total moles of organic acid is about 50:1.

21. The vaporizable composition of claim 18 , wherein the (w/v) concentration of (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine in the vaporizable alkaloid composition is from about 1 mg/mL to about 1,000 mg/mL.

22. The vaporizable composition of claim 18 , wherein the (w/v) concentration of (S)-2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine in the vaporizable alkaloid composition is about 100 mg/mL.

23. The vaporizable alkaloid composition of claim 18 , wherein the at least one organic acid consists of a mixture of citric acid and acetic acid.

24. The vaporizable alkaloid composition of claim 18 , wherein the solvent is selected from the group consisting of propylene glycol, glycerin, ethanol, and mixtures thereof.

25. The vaporizable alkaloid composition of claim 19 , wherein the spice additive comprises capsaicin.

26. The vaporizable alkaloid composition of claim 1 , further comprising methyl salicylate or ethyl vanillin.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2024
From: OWEN, CHARLOTTE L.; AVILA, RICHARD, JR.; HABICHT, GEOFF W.
To: READY MIX NATURALS, LLC
Reel/Frame 067300/0478 →
Continuity (3)
Continuation 18227815 · Jul 28, 2023
Provisional Application 63439650 · Jan 18, 2023
Related Publication 20240246930A1 · Jul 25, 2024
References Cited (46)
US 4922901A · Brooks · 1990 [cited by examiner]
US 5242935A · Lippiello · 1993 [cited by examiner]
US 6041789A · Bankert et al. · 2000 [cited by applicant]
US 10973255B2 · Pandolfino · 2021 [cited by applicant]
US 20030225142A1 · Crooks · 2003 [cited by examiner]
US 20040123873A1 · Calandro et al. · 2004 [cited by applicant]
US 20130157995A1 · Kem et al. · 2013 [cited by applicant]
US 20130192620A1 · Tucker et al. · 2013 [cited by applicant]
US 20140190478A1 · Liu · 2014 [cited by applicant]
US 20140271946A1 · Kobal · 2014 [cited by examiner]
US 20170189388A1 · Arnold · 2017 [cited by applicant]
US 20170325494A1 · Cameron et al. · 2017 [cited by applicant]
US 20180184704A1 · Williams · 2018 [cited by applicant]
US 20210112863A1 · Hon · 2021 [cited by applicant]
US 20210195938A1 · Mua et al. · 2021 [cited by applicant]
US 20230211907A1 · Skeberg · 2023 [cited by applicant]
US 20240245092A1 · Owen et al. · 2024 [cited by applicant]
US 20240270711A1 · Owen et al. · 2024 [cited by applicant]
US 20240350476A1 · Tanakit et al. · 2024 [cited by applicant]
US 20240400539A1 · Owen et al. · 2024 [cited by applicant]
CN 104473322A · 2015 [cited by applicant]
CN 114403494A · 2022 [cited by applicant]
CN 114437025A · 2022 [cited by applicant]
WO 2015148649A1 · 2015 [cited by applicant]
WO 2020205811A1 · 2020 [cited by applicant]
WO 2022053621A1 · 2022 [cited by applicant]
Machine translation of CN102273322A, Google Patents, [online], retrieved from the internet, [retrieved Nov. 22, 2023, <URL:https:// patents.google.com/patenUCN 104473322A/en>. (Year: 2023). [cited by applicant]
Non-Final Office Action dated Dec. 1, 2023 in U.S. Appl. No. 18/227,815. [cited by applicant]
Pubchem, CID 129890930, Sep. 13, 2017, entire document, especially p. 2, compound listed. [cited by applicant]
Patent Cooperation Treaty, International Search Report & Written Opinion in Application No. PCT/US2023/029034, mailed Jan. 10, 2024. [cited by applicant]
United States Patent and Trademark Office, Restriction Requirement received in U.S. Appl. No. 18/227,815 dated Oct. 25, 2023. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action received in U.S. Appl. No. 18/227,815 dated Dec. 1, 2023. [cited by applicant]
United States Patent and Trademark Office, Notice of Allowance received in U.S. Appl. No. 18/227,815 dated Mar. 22, 2024. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action received in U.S. Appl. No. 18/799,650 dated Sep. 27, 2024. [cited by applicant]
Patent Cooperation Treaty, International Search Report & Written Opinion in Application No. PCT/US2024/045553, mailed Jan. 22, 2025. [cited by applicant]
Patent Cooperation Treaty (PCT), International Search Report and Written Opinion received in Application No. PCT/US2024/042756, Nov. 21, 2024. [cited by applicant]
Pogocki et al., Application of nicotine enantiomers, derivatives and analogues in therapy of neurodegenerative disorders, European Journal of Parmacology, 2007, 563, pp. 18-39, especially: p. 19, Fig. 1, formula nornico… [cited by applicant]
Liu et al., Analysis of nicotine and nicotine-related compounds in electronic cigarette liquids and aerosols by liquid chromatography-tandem mass spectrometry, Beitrage zur Tabakforschhung International/Contributions to… [cited by applicant]
Hukkanen, et al., Metabolism and disposition kinetics of nicotine, Pharmacological Reviews. 2005. vol. 57, No. 1, pp. 79-115, entire document. [cited by applicant]
Owen, et al, Tobacco Harm Reduction and Pain Relief Products and Methods Thereof, U.S. Appl. No. 18/826,821, filed Sep. 6, 2024. [cited by applicant]
Owen, et al, Vaporizable Alkaloid Compositions and Methods of Use Thereof, U.S. Appl. No. 18/926,671, filed Oct. 25, 2024. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action received in U.S. Appl. No. 18/807,086 dated Dec. 9, 2024. [cited by applicant]
Patent Cooperation Treaty, International Search Report & Written Opinion in Application No. PCT/US2024/052615, mailed Feb. 3, 2025. [cited by applicant]
Green et al. 'Nornicotine pretreatment decreases intravenous nicotine self-administration in rats Psychopharmacology. Aug. 19, 2000, vol. 152, p. 289-294 entire document. [cited by applicant]
The United States Patent and Trademark Office, Non-Final Office Action Received in U.S. Appl. No. 18/826,821, mailed Jun. 10, 2025. [cited by applicant]
Seeman et al., “Nicotine Chemistry. The Addition Alkyl Radicals to (S)-(-)-Nicotine: Sythesis of Optically Active 6-Alkylnicotines,” Oct. 1995. [cited by applicant]